I Hate Dialysis Message Board
Welcome, Guest. Please login or register.
November 25, 2024, 03:35:46 AM

Login with username, password and session length
Search:     Advanced search
532606 Posts in 33561 Topics by 12678 Members
Latest Member: astrobridge
* Home Help Search Login Register
+  I Hate Dialysis Message Board
|-+  Dialysis Discussion
| |-+  Dialysis: News Articles
| | |-+  Making Money Off Medicare
0 Members and 1 Guest are viewing this topic. « previous next »
Pages: [1] Go Down Print
Author Topic: Making Money Off Medicare  (Read 1261 times)
okarol
Administrator
Member for Life
*****
Offline Offline

Gender: Female
Posts: 100933


Photo is Jenna - after Disneyland - 1988

WWW
« on: July 03, 2008, 12:01:07 AM »

Monday, 30 Jun 2008
Making Money Off Medicare
Posted By:Tom Brennan
Topics:Stock Picks | Stock Market
Sectors:Health Care | Health Care Equipment and Services
Companies:DaVita Inc. | Fresenius Medical Care Corporation

Dialysis providers are one group that Cramer said could get a boost from an updated Medicare bill.

A current version of the bill – finally – provides these dialysis companies with annual base-rate and inflation-rate payment increases. Up until now, dialysis was one of the few groups without an annual update formula. The measure will offer better visibility – and earnings – going forward.

So which company’s most likely to benefit? Well, DaVita
DAVITA INC - DVA 53.37  0.24  +0.45%
and Fresenius
FRESENIUS MEDICAL CARE AG & CO. - FMS 55.14  -0.85  -1.52%
together control 65% of the U.S. dialysis market, but Cramer leans toward the latter because of its overseas exposure. Both companies are great, and all dialysis providers will benefit from the bill, but Fresenius is clearly the best-of-breed stock here.

FMS is the only vertically integrated dialysis company in the world. It makes the tubes, supplements, drugs and machines in addition to putting them to use. This business model allows Fresenius access to countries where it doesn’t have facilities or permission to operate. (Some countries don’t allow private dialysis providers.)

The good news is that these countries are higher growth markets. The dialysis business in China is growing at 30% to 40%, and FMS has a presence there. The company’s set up shop in Europe, Latin America and the Asia Pacific region, too.

FMS trades at a premium to DaVita, but Cramer said that comes with the territory when you’re a more efficient company. Taking that premium into account, Fresenius should be worth $65 a share rather than its present price of just under $55.

And that’s not taking into account the earnings estimates Cramer thinks are too low. If those come up – and he’s betting they will – FMS stock should follow.

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com

http://www.cnbc.com/id/25457755
Logged


Admin for IHateDialysis 2008 - 2014, retired.
Jenna is our daughter, bad bladder damaged her kidneys.
Was on in-center hemodialysis 2003-2007.
7 yr transplant lost due to rejection.
She did PD Sept. 2013 - July 2017
Found a swap living donor using social media, friends, family.
New kidney in a paired donation swap July 26, 2017.
Her story ---> https://www.facebook.com/WantedKidneyDonor
Please watch her video: http://youtu.be/D9ZuVJ_s80Y
Living Donors Rock! http://www.livingdonorsonline.org -
News video: http://www.youtube.com/watch?v=J-7KvgQDWpU
Pages: [1] Go Up Print 
« previous next »
 

Powered by MySQL Powered by PHP SMF 2.0.17 | SMF © 2019, Simple Machines | Terms and Policies Valid XHTML 1.0! Valid CSS!